Hematology Faculty

Division Chief

Linda M. Boxer, MD, PhD

  • The molecular mechanisms of deregulation of the oncogenes, c-myc and bcl-2, by translocation into immunoglobulin loci
  • How deregulation of these oncogenes disrupts the normal regulatory control mechanisms in hematopoietic cells
  • Identification of critical genes and pathways in acute lymphoblastic leukemia in response to chemotherapeutic agents


Steven E. Artandi, MD, PhD

  • Understanding how telomere shortening influences cell fates and how it leads to chromosomal instability and promotes initiation of tumoigenesis
  • Characterizing how telomerase reactivation during tumor development facilitates cell survival and promotes tumor maturation
  • Approaches to dissect oncogene and tumor suppressor function in the normal biology of the breast and in breast cancer formation using the mouse as a model system

Ami Bhatt, MD, PhD

Assistant Professor

Our laboratory uses molecular, micro- and computational biology techniques to dissect the role of the microbiota in hematological disorders.

We hope to target vulnerabilities in hematological disorders characterizing and modifying the human microbiota, thereby improving patient outcomes.

Caroline Bérubé, MD
Clinical Associate Professor

Steven E. Coutré, MD
Associate Professor

Clinical evaluation of platelet antagonists, hematopoietic growth factors and novel antithrombotics Development of clinical protocols for the treatment of hematologic malignancies including acute and chronic leukemias and multiple myeloma Director, Stanford Hematology Clinic

Lawrence Tim Goodnough, MD
Professor, Pathology & Medicine

  • Director of Transfusion Service
  • Oversees and supervises rotation in transfusion service
  • Associate Director of Quality, Department of Pathology
  • Director, Transfusion Medicine Fellowship Program
  • Associate Medical Director, Stanford Blood Center

Jason R. Gotlib, MD
Associate Professor

Phase I/II trial evaluation of novel therapies for myelodysplastic syndromes, acute myelogenous leukemia, chronic myelogenous leukemia, and chronic myeloproliferative disorders (MPDs, eg. polycythemia vera, essential thrombocythemia, primary myelofibrosis, hypereosinophilic syndromes, and systemic mastocytosis) Translational research collaborations to interrogate the molecular basis of CML and chronic MPDs
MPDs Associate Director, Stanford Myelodysplastic Syndromes Center Director, Hematology Division Tissue Bank Director, Med 8, Inpatient Hematology Service Director, Hematology Fellowship Program

Peter L. Greenberg, MD
Professor, Emeritus (Active)

  • The role and mechanisms of programmed cell death (apoptosis), oncoprotein/oncogene expression, and anti-angiogenesis in hemopoietic regulation
  • Focus is given to evaluating these processes in the evolution of myelodysplastic syndromes and acute myeloid leukemia in vitro and in vivo, with emphasis on the impact of hemopoietic growth factors
  • Development of clinical protocols for treating myelodysplastic syndrome and acute myeloid leukemias
  • Director, MDS Center

Calvin J. Kuo, MD, PhD

  • Assessment of therapeutic efficacy of novel anti-angiogenic factors using adenoviral, knockout and corneal micropocket assays in mice
  • Biology and signaling mechanisms of novel vascular G-protein coupled receptors in mice and zebrafish
  • Roles of Wnt signaling in adult physiology using adenoviral and transgenic approaches

Lawrence L.K. Leung, MD
The Maureen Lyles D'Ambrogio Professor

  • The discovery and development of new antithrombotic reagents, targeting plasma proteases and their inhibitors, and cell adhesive proteins and their receptors on platelets and endothelial cells
  • Approaches include basic molecular and protein biochemistry to the evaluation in appropriate animal models

Michaela Liedtke, MD
Assistant Professor

Characterization of the molecular mechanism of MLL-induced acute leukemia and development of new therapeutic strategies for this disease Design of phase I/II trials for the treatment of acute and chronic leukemia and multiple myeloma with novel experimental agents

Ravi Majeti, MD, PhD
Assistant Professor

Molecular characterization of human acute myeloid leukemia stem cells and their pathogenesis using bioinformatics, genomics, microfluidics, flow cytometry, and xenotransplantation assays in mice Development of novel therapeutic monoclonal antibodies directed against human acute myeloid leukemia stem cell surface antigens Investigation of normal human hematopoiesis and hematopoietic stem cells using similar techniques

Beth A. Martin, MD
Clinical Assistant Professor (Affiliated)

Research interests include supportive care Educational interests include malignancy: decision-making and communication skills; stress management; physical diagnosis Clinical interests include multiple myeloma and general hematology-oncology

Bruno Medeiros, MD
Associate Professor

Development of novel therapeutic strategies for the treatment of myeloid, lympoid, acute and chronic leukemias as well as multiple myeloma

Beverly S. Mitchell, MD
George E. Becker Professor of Medicine

  • Role of nucleotides in regulating nucleolar organization, function and cell proliferation
  • Novel therapies for acute leukemia with correlative studies
  • Function of a novel DNA repair protein with ubiquitin ligase activity

Elizabeth A. Price, MD, MPH
Assistant Professor

Clinical and laboratory characterization of unexplained anemia of aging Development of clinical protocol evaluating hematologic and functional response to interventions in unexplained anemia of aging


Stanley L. Schrier, MD
Professor, Emeritus (Active)

Red cell biology with emphasis on the pathophysiology and cell biology of the thalassemias, the causes of anemia in malaria, and the complex consequences of anemia in the aged

James L. Zehnder, MD

Clinical and laboratory investigation of thrombosis and bleeding disorders Molecular diagnostic testing for inherited thrombophilia and hematololymphoid malignancy